相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms
Joelle Lapoirie et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2020)
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
Kai Wille et al.
ANNALS OF HEMATOLOGY (2019)
Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
Alexandre Guy et al.
HAEMATOLOGICA (2019)
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
Tarinee Rungjirajittranon et al.
BMC CANCER (2019)
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms A Population-Based Cohort Study
Malin Hultcrantz et al.
ANNALS OF INTERNAL MEDICINE (2018)
Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders
Abdulkerim Yildiz et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
Guido Finazzi et al.
BLOOD CANCER JOURNAL (2018)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Polycythemia vera treatment algorithm 2018
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges
Paola Lanuti et al.
SCIENTIFIC REPORTS (2018)
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Baerbel Edelmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features
Anna Guadall et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy
Martin Griesshammer et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series
Graeme Greenfield et al.
THROMBOSIS JOURNAL (2018)
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms
Valentina Rosso et al.
ONCOTARGET (2017)
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
Jean-Christophe Ianotto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis
Leslie Skeith et al.
BLOOD (2017)
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians
A. Kaifie et al.
ANNALS OF HEMATOLOGY (2016)
JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms
Chi Hua Sarah Lin et al.
BLOOD CELLS MOLECULES AND DISEASES (2016)
Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study
Samah Alimam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
V. De Stefano et al.
LEUKEMIA (2016)
Innovative Flow Cytometry Allows Accurate Identification of Rare Circulating Cells Involved in Endothelial Dysfunction
Federica Boraldi et al.
PLOS ONE (2016)
Haematological malignancies in pregnancy: An overview with an emphasis on thrombotic risks
Netanel A. Horowitz et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment
Valerio De Stefano et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
V. De Stefano et al.
BLOOD CANCER JOURNAL (2016)
Hematologic malignancies during pregnancy: A review
Hossam K. Mahmoud et al.
JOURNAL OF ADVANCED RESEARCH (2016)
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Juan-Carlos Hernandez-Boluda et al.
ANNALS OF HEMATOLOGY (2015)
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
Tiziano Barbui et al.
BLOOD (2015)
Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review
Antonio Gomez-Outes et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study
Ida Martinelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia
Maria Luigia Randi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (A-GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)
Stephan Kreher et al.
ANNALS OF HEMATOLOGY (2014)
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms
Raajit Rampal et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
Guido Finazzi et al.
BLOOD (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms
S. Leah Etheridge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Essential thrombocythemia as a risk factor for stillbirth
Takeshi Umazume et al.
THROMBOSIS RESEARCH (2014)
Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey
Martin H. Ellis et al.
THROMBOSIS RESEARCH (2014)
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
Vittorio Rosti et al.
BLOOD (2013)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia
Carlo Patrono et al.
BLOOD (2013)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis
Tiziano Barbui et al.
BLOOD (2013)
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice
A. Tefferi et al.
LEUKEMIA (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: A role for the JAK2 V617F mutation re-evaluation
Donatella Colaizzo et al.
THROMBOSIS RESEARCH (2013)
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Silvia Pascale et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
Myeloproliferative Neoplasms
Julie Kim et al.
DM DISEASE-A-MONTH (2012)
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH
T. BAGLIN et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report
Marc L. Berger et al.
VALUE IN HEALTH (2012)
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
Marina Panova-Noeva et al.
BLOOD (2011)
Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms
Luciana Teofili et al.
BLOOD (2011)
Recommendations for Planning Pilot Studies in Clinical and Translational Research
Charity G. Moore et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2011)
MicroRNA-mediated regulation of the angiogenic switch
Sudarshan Anand et al.
CURRENT OPINION IN HEMATOLOGY (2011)
Essential thrombocythemia and pregnancy
Marie-Cecile Valera et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2011)
Myeloproliferative Disorders in Pregnancy
Claire N. Harrison et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy
Alfredo Dragani et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway
Yanmin Dong et al.
CARCINOGENESIS (2010)
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients
Francesca Palandri et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies
F. Passamonti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting
C. Kearon et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker
Giovanna Piaggio et al.
BLOOD (2009)
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Francesco Dentali et al.
BLOOD (2009)
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
Selcuk Sozer et al.
BLOOD (2009)
Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo
Selcuk Sozer et al.
BLOOD CELLS MOLECULES AND DISEASES (2009)
Green tea catechins inhibit angiogenesis through suppression of STAT3 activation
Hoyee Leong et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy
Martin Griesshammer et al.
BLOOD REVIEWS (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Leukocytosis and risk stratification assessment in essential thrombocythemia
Alessandra Carobbio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
The microRNA.org resource: targets and expression
Doron Betel et al.
NUCLEIC ACIDS RESEARCH (2008)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Epidemiology and risk factors for venous thrombosis
Mary Cushman
SEMINARS IN HEMATOLOGY (2007)
Essential thrombocythemia/polycythemia vera and pregnancy: The need for an observational study in Europe
Martin Griesshammer et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
VEGF differentially activates STAT3 in microvascular endothelial cells
M Bartoli et al.
FASEB JOURNAL (2003)
Endothelial cells in the bone marrow of patients with multiple myeloma
A Vacca et al.
BLOOD (2003)
Endothelial dysfunction in patients with polycythaemia vera
T Neunteufl et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
